Pulmatrix, Inc. (PULM)

Market Cap	5.00M -78.9%
Revenue (ttm)	n/a
Net Income	-4.53M
EPS	-1.24
Shares Out	3.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,194
Open	1.300
Previous Close	1.320
Day's Range	1.300 - 1.370
52-Week Range	1.160 - 9.230
Beta	1.94
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About PULM

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in ch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: PULM
• Website: https://www.pulmatrix.com